Page last updated: 2024-11-11

ps 15

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

PS 15: structure given in first source; inhibitor of tetrahydrofolate dehydrogenase [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9571109
CHEMBL ID127105
SCHEMBL ID1742217
MeSH IDM0220159

Synonyms (11)

Synonym
ps 15
imidodicarbonimidic diamide, n-(1-methylethyl)-n'-(3-(2,4,5-trichlorophenoxy)propoxy)-, hydrochloride
1-isopropyl-3-[n-[3-(2,4,5-trichlorophenoxy)propoxy]carbamimidoyl]guanidine
wr-250417
152662-90-3
ps-15
CHEMBL127105
SCHEMBL1742217
n-propan-2-yl-n'-[3-(2,4,5-trichlorophenoxy)propoxy]triimidodicarbonic diamide
DTXSID50934563
(1e)-1-[amino-[3-(2,4,5-trichlorophenoxy)propoxyamino]methylidene]-2-propan-2-ylguanidine

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
" When PS-15 was administered in combination with sulfamethoxazole to healthy Saimiri sciureus monkeys, the serum antimalarial activity was considerably greater than that observed in monkeys that received PS-15 alone."( The activity of PS-15 in combination with sulfamethoxazole.
Rieckmann, KH; Yeo, AE, 1994
)
0.29

Dosage Studied

ExcerptRelevanceReference
" Four monkeys were orally dosed with 40 mg/kg/day of WR250417 over three days (-1, 0, and +1)."( Evaluation of WR250417 (a proguanil analog) for causal prophylactic activity in the Plasmodium cynomolgi-Macaca mulatta model.
Corcoran, KD; Edstein, MD; Hansukjariya, P; Ngampochjana, M; Rieckmann, KH; Sattabongkot, J; Shanks, GD; Webster, HK, 1994
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID140724Dose required for 100%, 31 day survival of Plasmodium berghei inoculated mice (Mus musculus).2001Journal of medicinal chemistry, Nov-08, Volume: 44, Issue:23
Phenoxypropoxybiguanides, prodrugs of DHFR-inhibiting diaminotriazine antimalarials.
AID248853In vitro antimalarial activity for DHFR wild-type, chloroquine and pyrimethamine-sensitive Plasmodium falciparum D62005Journal of medicinal chemistry, Apr-21, Volume: 48, Issue:8
In vitro metabolism of phenoxypropoxybiguanide analogues in human liver microsomes to potent antimalarial dihydrotriazines.
AID236272Michaelis-Menten constant value against human liver microsomes; (n=6)2005Journal of medicinal chemistry, Apr-21, Volume: 48, Issue:8
In vitro metabolism of phenoxypropoxybiguanide analogues in human liver microsomes to potent antimalarial dihydrotriazines.
AID225685In vivo antimalarial activity against Plasmodium berghei in mice (Mus musculus) after 6 days2001Journal of medicinal chemistry, Nov-08, Volume: 44, Issue:23
Phenoxypropoxybiguanides, prodrugs of DHFR-inhibiting diaminotriazine antimalarials.
AID237027Maximum velocity against human liver microsomes; (n=6)2005Journal of medicinal chemistry, Apr-21, Volume: 48, Issue:8
In vitro metabolism of phenoxypropoxybiguanide analogues in human liver microsomes to potent antimalarial dihydrotriazines.
AID127816Dose needed to increase the 100% survival of treated animals (mouse), to twice the number of days2001Journal of medicinal chemistry, Nov-08, Volume: 44, Issue:23
Phenoxypropoxybiguanides, prodrugs of DHFR-inhibiting diaminotriazine antimalarials.
AID248852In vitro antimalarial activity for DHFR wild-type, chloroquine and pyrimethamine-resistant Plasmodium falciparum W22005Journal of medicinal chemistry, Apr-21, Volume: 48, Issue:8
In vitro metabolism of phenoxypropoxybiguanide analogues in human liver microsomes to potent antimalarial dihydrotriazines.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's11 (78.57)18.2507
2000's3 (21.43)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]